Alumis Inc.
ALMS
Pozycja w akcjach
#10424
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Cena akcji
$6.15
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$795.38M
Zmiana (1 dzień)
-2.61%
Zmiana (1 rok)
170.70%
Kraj
US
Handel Alumis Inc. (ALMS)
Kategoria
Healthcare
EPS dla Alumis Inc. (ALMS)
EPS na dzień March 2025 TTM: $-2.70
Według najnowszych raportów finansowych i ceny akcji firmy Alumis Inc., obecny EPS (TTM) wynosi $-2.70. Na koniec roku 2023 firma miała EPS w wysokości $-5.43, wzrost w porównaniu do do EPS z roku 2022, który wynosił $-0.70.
Historia EPS dla Alumis Inc. od 2021 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
